SCHEMBL6096883

SCHEMBL6096883

CCCCCNc1ccccc1/C=N\O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.40
CNR2 P34972 4/20 0.40
CNR1 P21554 1/20 0.39
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
APAF1 O14727 1/20 0.38
HSP90AA1 P07900 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
BLM P54132 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KCNH3 Q9ULD8 1/20 0.38
NPC1 O15118 1/20 0.37
ALOX12 P18054 1/20 0.37
RAB9A P51151 1/20 0.37
USP2 O75604 1/20 0.37
NAAA Q02083 3/20 0.36
ALDH1A1 P00352 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096888 1.00 L3MBTL1 (0.40) L3MBTL1CNR2CNR1MAPTMEN1
SCHEMBL4954523 0.80 L3MBTL1 (0.43) L3MBTL1CNR2CNR1MAPTHTT
SCHEMBL11623780 0.80 L3MBTL1 (0.43) L3MBTL1CNR2CNR1MAPTHTT
SCHEMBL4958966 0.80 L3MBTL1 (0.43) L3MBTL1CNR2CNR1MAPTHTT
SCHEMBL7560980 0.79 L3MBTL1 (0.43) L3MBTL1CNR2CNR1MAPTHTT
SCHEMBL4958970 0.79 L3MBTL1 (0.43) L3MBTL1CNR2CNR1MAPTHTT
SCHEMBL1506754 0.79 L3MBTL1 (0.43) L3MBTL1CNR2CNR1MAPTHTT
SCHEMBL7285847 0.79 L3MBTL1 (0.46) L3MBTL1CNR2CNR1MEN1BLM
SCHEMBL23248725 0.78 L3MBTL1 (0.45) L3MBTL1CNR2CNR1SMN1; SMN2NPSR1
SCHEMBL10628478 0.78 L3MBTL1 (0.45) L3MBTL1CNR2CNR1SMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6998489-B2 Methods of making indazoles ALCON, INC. (CH) 2006-02-14 US disclosed
EP-1392659-A4 METHODS OF MAKING INDAZOLES ALCON INC (CH) 2004-10-20 EP disclosed
US-20040142998-A1 Methods of making indazoles ALCON, INC. (CH) 2004-07-22 US disclosed
EP-1392659-A1 METHODS OF MAKING INDAZOLES Alcon, Inc. (CH) 2004-03-03 EP disclosed
WO-2002098862-A1 METHODS OF MAKING INDAZOLES ALCON, INC. (CH) 2002-12-12 WO disclosed
WO-2002098861-A1 METHODS OF MAKING 1-(2-AMINOPROPYL)-6-HYDROXYINDAZOLE ALCON, INC. (CH) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142998-A1 Methods of making indazoles NAT1, CYP3A5, ALDH3A1 L3MBTL1 4474/4885CNR2 1033/4885CNR1 1681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.